Review Article

ADIPOSE TISSUE AS AN ENDOCRINE ORGAN: BIOCHEMICAL MEDIATORS IN OBESITY AND METABOLIC SYNDROME

Nagadharshan Devendra[1], Uma Sankar Akula[2], Noor Lais[3], Marlene Zahran[4]

[1-4]*Trinity Medical Sciences University, Ratho Mill Campus, Saint Vincent and Grenadines, West Indies.*

Received *: 30/01/2026*
Received in revised form *: 18/03/2026*
Accepted *: 02/04/2026*

Corresponding Author:
Dr. Nagadharshan Devendra,
Professor of Biochemistry and Associate Dean of Education, Trinity Medical Sciences University, Ratho Mill Campus, Saint Vincent and Grenadines.West Indies
Email: ndevendra@tmsu.edu.vc

DOI: 10.70034/ijmedph.2026.2.365

Source of Support: Nil,
Conflict of Interest: None declared

Int J Med Pub Health
2026; 16 (2); 2180-2190

ABSTRACT

Background: Adipose tissue is now widely recognized as an active endocrine organ rather than a passive site for triglyceride storage. In addition to its central role in energy balance, adipose tissue secretes a broad spectrum of bioactive mediators, including adipokines, cytokines, chemokines, vascular regulators, and extracellular signaling molecules that influence metabolism, inflammation, insulin sensitivity, and cardiovascular homeostasis.

Discussion: This review examines the endocrine functions of adipose tissue and highlights the major biochemical mediators involved in the development of obesity and metabolic syndrome. Particular attention is given to the structural and functional remodeling of adipose tissue during obesity, including adipocyte hypertrophy, hypoxia, extracellular matrix stress, fibrosis, and immune-cell infiltration, all of which contribute to a pathological shift in adipose secretory activity. The review discusses the roles of key adipose-derived mediators, including leptin, adiponectin, TNF-α, IL-6, resistin, MCP-1, PAI-1, chemerin, omentin, RBP4, and other emerging signaling factors involved in inter-organ communication.

Conclusion: These mediators collectively link excess adiposity with insulin resistance, chronic low-grade inflammation, endothelial dysfunction, altered lipid handling, and prothrombotic states. The review also emphasizes that adipose tissue is heterogeneous, with visceral and subcutaneous depots exhibiting distinct endocrine and metabolic properties, thereby influencing disease risk differently. Importantly, adipose endocrine dysfunction is presented not only as a consequence of obesity but also as a driver of disease progression through persistent inflammatory and metabolic signaling.

Keywords: Adipose tissue; adipokines; obesity; metabolic syndrome; endocrine dysfunction.

INTRODUCTION

Adipose tissue is now recognized as far more than a passive reservoir for triglyceride storage. Over the past several decades, it has emerged as a highly active endocrine and paracrine organ that continuously exchanges signals with the brain, liver, skeletal muscle, pancreas, vasculature, and immune system.[1] This conceptual shift has profoundly altered the biological understanding of obesity. Rather than being viewed solely as a disorder of excessive fat accumulation, obesity is now understood as a condition in which adipose tissue undergoes functional and secretory reprogramming, producing mediators that influence systemic metabolism, inflammation, vascular homeostasis, and insulin sensitivity. The identification of adipose-derived and adipose-associated factors such as tumor necrosis factor-α, adiponectin, interleukin-6, angiotensinogen, and plasminogen activator inhibitor-1 provided early and compelling evidence that adipose tissue exerts important hormonal functions well beyond energy storage. These discoveries established adipose tissue as a biologically dynamic organ whose endocrine activity plays a central role in the pathogenesis of obesity-related metabolic disease.[2]

Under normal physiological conditions, adipose tissue contributes fundamentally to whole-body energy homeostasis. It stores excess energy in the form of triglycerides during periods of nutrient abundance and releases fatty acids during fasting or increased energy demand. However, its physiological role extends well beyond lipid buffering. Adipocytes and the stromal vascular fraction synthesize and secrete a broad range of

bioactive molecules, including hormones, cytokines, chemokines, growth factors, lipid mediators, and extracellular matrix-remodeling proteins, which act in autocrine, paracrine, and endocrine fashions. Through these signals, adipose tissue participates in the regulation of appetite, insulin action, immune responses, angiogenesis, reproductive function, and vascular biology. In metabolically healthy states, this endocrine output supports flexibility in substrate utilization, preserves insulin responsiveness, and promotes appropriate tissue remodeling. Thus, adipose tissue should be regarded not simply as an energy depot, but as an active integrative organ that contributes to the maintenance of metabolic equilibrium.[2,3]

The endocrine behavior of adipose tissue becomes particularly important in obesity, where tissue expansion is accompanied by profound structural and functional alterations. As adipocytes enlarge, local oxygen tension may decline, extracellular matrix organization becomes disturbed, and the tissue microenvironment shifts toward chronic low-grade inflammation. These changes are accompanied by immune-cell recruitment, especially macrophage infiltration, and by alterations in the balance of secreted factors. Protective adipokines may decline, while pro-inflammatory and metabolically adverse mediators become more prominent. This secretory imbalance contributes to impaired insulin signaling, disturbed lipid metabolism, endothelial dysfunction, and systemic inflammatory activation. Therefore, the pathophysiological significance of adipose tissue in obesity lies not only in the amount of fat present, but also in the altered quality of the tissue and the dysregulated endocrine profile that accompanies its expansion.[3]

Another important feature of adipose tissue is its anatomical and functional heterogeneity. Adipose depots are not biologically identical, and their endocrine behavior differs according to location. Subcutaneous and visceral adipose tissues vary in developmental origin, vascular supply, innervation, cellular composition, and secretory characteristics. Among these depots, visceral adipose tissue is especially relevant to metabolic syndrome because of its strong association with insulin resistance, dyslipidemia, hypertension, and increased cardiometabolic risk. Its proximity to the portal circulation also supports a more direct influence on hepatic metabolism. For this reason, adipose tissue is more accurately viewed as a distributed endocrine system composed of distinct depots with differing metabolic consequences. This perspective helps explain why fat distribution, inflammatory status, and remodeling capacity may be as clinically important as total fat mass itself.[4]

The cellular origin of adipose-derived mediators further adds to the complexity of this organ. The secretory output of adipose tissue is not produced solely by mature adipocytes. Although adipocytes are major sources of hormones such as adiponectin and other classic adipokines, many inflammatory mediators arise from macrophages, endothelial cells, fibroblasts, preadipocytes, and other cells within the stromal vascular fraction. In obesity, adipocyte hypertrophy is frequently followed by recruitment and activation of immune cells, which intensify inflammatory signaling and amplify local tissue dysfunction. As a result, the endocrine activity of adipose tissue reflects not only adipocyte biology, but also the integrated contribution of multiple interacting cell populations within the adipose microenvironment. This multicellular secretory network is central to the modern concept of adipose tissue as an immunometabolic organ.[5]

The clinical importance of this endocrine dysfunction becomes especially evident in metabolic syndrome. Central obesity, insulin resistance, dyslipidemia, hypertension, and a prothrombotic state are not isolated abnormalities; rather, they are interrelated manifestations of disturbed communication among metabolic tissues. Adipose-derived mediators influence appetite regulation, hepatic glucose production, peripheral glucose uptake, lipid turnover, coagulation pathways, vascular reactivity, and inflammatory tone. Some adipokines exert beneficial and insulin-sensitizing actions, whereas others promote inflammation, endothelial dysfunction, and metabolic deterioration. Accordingly, no single adipose-derived mediator is sufficient to explain the full pathophysiology of obesity-associated disease. Instead, the clinical phenotype appears to arise from the cumulative imbalance between protective and pathogenic endocrine signals generated by dysfunctional adipose tissue.

An equally important concept is that adipose endocrine dysfunction is not merely a consequence of obesity, but also an active participant in disease progression. Once adipose tissue becomes inflamed, hypoxic, and fibrotic, its altered secretory profile can worsen insulin resistance, encourage ectopic lipid deposition, impair vascular homeostasis, and perpetuate chronic systemic inflammation. This creates a feed-forward cycle in which adipose dysfunction accelerates the very metabolic disturbances that promote further tissue injury. Such a model helps explain why obesity and metabolic syndrome are persistent, multisystem disorders rather than simple disorders of excess body weight. It also highlights adipose tissue as a key therapeutic target. Strategies aimed at improving adipose tissue quality, restoring a healthier adipokine balance, and promoting more adaptive tissue remodeling may offer metabolic benefit even before major reductions in fat mass occur.[6] The objective of this review is to synthesize current evidence on adipose tissue as an endocrine organ and to highlight the role of

adipose-derived biochemical mediators in the pathogenesis of obesity and metabolic syndrome."

Methods

This narrative review was conducted using a structured search of electronic databases, including PubMed. The search focused primarily on literature published between 2000 and 2025, with particular emphasis on studies from the past 10-15 years that directly address the endocrine functions of adipose tissue and their role in obesity and metabolic syndrome.

Search terms included " adipose tissue", "adipokines," "endocrine function," "obesity," "insulin resistance," "inflammation," and "metabolic syndrome," as well as specific mediators such as "leptin," "adiponectin," "TNF-α," and "IL-6." Additional relevant articles were identified through manual screening of reference lists.

Studies were selected based on their relevance to the objective of this review with priority given to recent peer-reviewed original research and review articles that provide mechanistic and clinical insight into adipose-derived mediators and their contribution to metabolic dysfunction. Earlier foundational studies were included selectively to provide essential background context but were not the primary focus of analysis.

Studies lacking direct relevance to adipose endocrine function or insufficient scientific rigor were excluded. The selected literature was analyzed and synthesized thematically to provide an integrated and up to date overview of adipose tissue as an endocrine organ in the pathogenesis of obesity and metabolic syndrome.

Adipose Expansion, Remodeling, and Endocrine Dysfunction

The endocrine consequences of obesity begin with the expansion and remodeling of adipose tissue. As adipose depots enlarge, adipocytes undergo hypertrophy and, in some cases, hyperplasia in an attempt to accommodate excess nutrient storage. This expansion is not biologically neutral. Progressive enlargement of adipocytes places mechanical stress on the extracellular matrix, disturbs local tissue architecture, and alters interactions between adipocytes and the stromal vascular compartment. As a result, adipose tissue gradually shifts from a relatively adaptive metabolic organ to a dysfunctional endocrine environment. Obesity-associated adipose tissue is characterized by increased infiltration of macrophages and other immune cells, many of which become important sources of inflammatory cytokines, chemokines, and other mediators that reshape local and systemic signaling. At the same time, vascular supply may fail to keep pace with tissue growth, creating areas of relative hypoxia that further disturb adipokine production, cellular metabolism, and secretory balance. These structural and cellular changes are central to the concept of adipose tissue dysfunction. In healthy adipose tissue, expansion can occur with relative metabolic flexibility, preserving insulin sensitivity and maintaining a secretory profile that supports energy homeostasis. In obesity, however, remodeling becomes maladaptive. Hypertrophic adipocytes are more vulnerable to cellular stress, altered lipolysis, and impaired insulin signaling, while the extracellular matrix becomes increasingly fibrotic and less permissive to healthy tissue expansion. This limits the storage capacity of adipose tissue and promotes spillover of lipid metabolites into the circulation and into non-adipose organs. Thus, adipose dysfunction is not merely a problem of increased mass, but also of reduced buffering capacity and altered endocrine behaviour.[7]

From an endocrine perspective, remodeling changes both the quantity and the quality of adipose output. As the tissue becomes inflamed and structurally abnormal, the pattern of secreted mediators shifts away from a metabolically protective state toward one that promotes insulin resistance, chronic inflammation, vascular dysfunction, and abnormal inter-organ communication. Adipokine imbalance becomes a defining feature of this altered state. Beneficial signals may decline, while pro-inflammatory and stress-related mediators become more prominent. This dysregulated secretome influences distant tissues such as the liver, skeletal muscle, pancreas, and vascular endothelium, thereby extending the pathological effects of adipose remodeling far beyond the fat depot itself. A maladaptively remodeled adipose depot also becomes an active participant in disease propagation. Crosstalk among adipocytes, macrophages, endothelial cells, fibroblasts, and preadipocytes reinforces inflammatory activation and sustains tissue dysfunction. Fibrosis, hypoxia, immune-cell recruitment, and altered lipid turnover interact in a feed-forward manner, making endocrine disruption progressively more severe as obesity advances. This is a major reason why obesity should not be understood simply as excess storage of fat. Rather, adipose tissue acquires a pathological endocrine identity, one capable of influencing whole-body metabolism, amplifying insulin resistance, and contributing directly to the development of metabolic syndrome.[8]



Figure 1: Pathophysiological progression of adipose tissue from metabolic homeostasis to endocrine dysfunction

Diagram depicting the sequential changes in adipose tissue during obesity, including expansion, structural remodeling, and disruption of endocrine function. These alterations promote a pro-inflammatory secretory profile and drive systemic metabolic disturbances such as insulin resistance and cardiovascular risk.

Leptin and Central-Peripheral Energy Signaling

Leptin is the archetypal adipose-derived hormone, and its discovery firmly established adipose tissue as an endocrine organ.[9,10] Produced predominantly by white adipocytes, leptin serves as a key signal of energy sufficiency, informing the central nervous system about the status of peripheral energy stores. Through its actions on hypothalamic pathways, leptin participates in the regulation of appetite, satiety, energy expenditure, neuroendocrine function, and reproductive physiology. The identification of the leptin receptor, OB-R, provided the mechanistic basis for understanding how adipose tissue communicates with the brain and confirmed that fat depots are integrated into broader homeostatic control systems. Under physiological conditions, leptin operates as part of a feedback loop that helps maintain energy balance. As adipose mass increases, leptin secretion rises, signaling the central nervous system to reduce food intake and increase energy expenditure. Conversely, when energy stores decline, leptin levels fall, promoting hunger and energy conservation. In this way, leptin functions as an endocrine indicator of nutritional status. Beyond appetite regulation, leptin also influences sympathetic activity, immune responses, reproductive hormone axes, and glucose metabolism, emphasizing that its biological role extends far beyond body weight regulation alone.[9]

In obesity, however, leptin exemplifies one of the most important paradoxes in endocrine physiology. Circulating leptin concentrations generally increase in proportion to fat mass, yet the expected anorexigenic and weight-limiting responses become blunted, a phenomenon commonly referred to as leptin resistance. This state reflects impaired responsiveness to a signal that is abundantly present, thereby disrupting the normal feedback relationship between adipose stores and central energy regulation. As a consequence, increased adiposity no longer produces an adequate biological signal to restrain further energy intake or promote sufficient energy expenditure. This decoupling of adipose mass from hypothalamic control contributes substantially to the persistence and progression of obesity. Leptin resistance has broad pathophysiological implications because leptin is not only a satiety hormone but also a pleiotropic mediator of immunometabolic communication. Altered leptin signaling can influence inflammatory pathways, autonomic tone, and peripheral metabolic regulation, linking excess adiposity to broader disturbances beyond appetite control. In this sense, leptin occupies a central position at the interface between adipose tissue and multiple organ systems. Its dysregulation illustrates how endocrine dysfunction in obesity involves not merely increased secretion of adipose-derived mediators, but also impaired target-organ responsiveness to those signals. Therefore, leptin should be viewed as both a marker and a mechanistic mediator of disrupted central-peripheral communication in obesity and

metabolic syndrome.[10] However, despite its well-established role in energy homeostasis, the mechanisms underlying leptin resistance remain complex and multifactorial, involving both central and peripheral regulatory processes that are not yet fully understood.

Adiponectin as the Counter-Regulatory Adipokine

Adiponectin is one of the most important counter-regulatory adipokines in metabolic disease. Unlike many adipose-derived mediators that increase with adiposity, inflammation, or adipose tissue stress, adiponectin is characteristically reduced in obesity, insulin resistance, and related metabolic disorders. This observation is conceptually important because it demonstrates that adipose tissue does not merely secrete factors that worsen metabolic dysfunction; it also produces protective signals, and the loss of these signals can itself contribute to disease pathogenesis. In this way, adiponectin represents a critical example of how adipose endocrine dysfunction in obesity involves not only the overproduction of harmful mediators but also the depletion of beneficial ones.

Physiologically, adiponectin is closely associated with insulin sensitization, fatty acid oxidation, glucose homeostasis, anti-inflammatory activity, and vascular protection. Its actions extend across multiple organs, particularly the liver and skeletal muscle, where it helps support metabolic flexibility and efficient nutrient handling. Adiponectin is therefore central to the maintenance of systemic metabolic balance. Its decline in obesity is especially significant because it removes an important protective brake against the development of insulin resistance, lipid dysregulation, and chronic low-grade inflammation. Rather than acting as a minor accessory hormone, adiponectin functions as a broad metabolic stabilizer whose deficiency can influence several interconnected features of metabolic syndrome.[11]

The importance of adiponectin was further strengthened by the identification of adiponectin receptors, which clarified the molecular basis through which adipose-derived signals regulate glucose and lipid metabolism in peripheral tissues. These receptors helped establish adiponectin as a true endocrine mediator rather than merely a biomarker of adipose health. Through receptor-mediated signaling, adiponectin contributes to improved insulin responsiveness, enhanced oxidative metabolism, and attenuation of inflammatory stress. As a result, adiponectin provides a mechanistic link between healthy adipose tissue function and protection against systemic metabolic deterioration.

From a pathophysiological perspective, adiponectin illustrates a key principle in obesity biology: endocrine dysfunction is not limited to the excessive secretion of pro-inflammatory cytokines and stress mediators. It also includes the loss of signals that normally preserve metabolic homeostasis. In obesity, the decline in adiponectin reflects a shift in adipose tissue from a protective endocrine phenotype to a dysfunctional one. This change has implications not only for insulin sensitivity but also for endothelial function, vascular integrity, and inflammatory balance, thereby placing adiponectin at the center of the broader relationship between adipose tissue and cardiometabolic disease. Adiponectin is therefore best understood as a counter-regulatory adipokine that opposes many of the metabolic disturbances associated with obesity. Its reduction is not simply a biochemical observation; it is a meaningful indicator of impaired adipose tissue quality and disordered endocrine communication. For this reason, adiponectin remains one of the most informative examples of how adipose tissue can exert both protective and pathogenic effects depending on its physiological state.[12]

TNF-α and IL-6 as Inflammatory Endocrine Mediators

TNF-α and IL-6 are among the best-known inflammatory mediators associated with dysfunctional adipose tissue and remain central to the modern understanding of obesity as a state of chronic low-grade inflammation.[13,14] Their importance lies in demonstrating that adipose tissue in obesity is not metabolically inert, but rather acts as an active source of inflammatory signals capable of altering systemic physiology. These cytokines helped redefine obesity as a disorder of immunometabolic dysregulation, in which adipose tissue contributes directly to impaired insulin action, altered substrate metabolism, and broader metabolic stress.

TNF-α is particularly important because of its close association with adipocyte dysfunction and impaired insulin signaling. Increased TNF-α activity within adipose tissue reflects the inflammatory transformation of the tissue microenvironment and contributes to the deterioration of normal adipocyte function. IL-6, although more complex in its biology, is likewise significant because it links adipose inflammation with wider systemic metabolic responses. It connects local adipose tissue dysfunction to broader disturbances involving hepatic metabolism, inflammatory tone, and endocrine regulation. Together, TNF-α and IL-6 illustrate how inflammatory mediators derived from adipose tissue can influence both local cellular behavior and whole-body metabolic homeostasis.[13]

These cytokines also demonstrate that endocrine signaling in obesity extends beyond classical hormones. Adipose tissue communicates not only through energy-balance hormones such as leptin and adiponectin, but also through inflammatory mediators that act in endocrine, paracrine, and autocrine fashions. This broadens the concept of

adipose tissue as an endocrine organ and underscores its close functional relationship with the immune system. In obesity, persistent exposure to TNF-α and IL-6 contributes to a tissue environment marked by cellular stress, inflammatory amplification, and altered metabolic responsiveness. Their sustained presence helps explain why metabolic syndrome is commonly accompanied by insulin resistance, endothelial dysfunction, and a pro-inflammatory systemic state.[14]

The importance of TNF-α and IL-6 therefore lies not only in their individual biological actions, but also in what they reveal about adipose tissue itself. Their expression indicates that obese adipose tissue has shifted from a relatively adaptive energy-storage organ to a source of chronic sterile inflammation. This inflammatory endocrine activity is a defining feature of adipose dysfunction and one of the key mechanisms linking obesity to metabolic disease.[13,14]

Resistin and MCP-1 in Immune-Metabolic Crosstalk

Resistin and MCP-1 are useful examples of adipose-associated mediators that connect inflammation with metabolic impairment and help explain how obesity evolves into a broader immunometabolic disorder. Resistin was initially proposed as a molecule linking obesity to diabetes, and its significance lies in highlighting the capacity of adipose-related signals to interfere with metabolic regulation. MCP-1, in contrast, is particularly important for its role in immune-cell recruitment, especially the attraction of monocytes and macrophages into adipose tissue. Together, these mediators demonstrate that the endocrine function of adipose tissue is deeply intertwined with immune activation and tissue inflammation.

In obesity, adipose tissue does not merely enlarge; it becomes progressively infiltrated by immune cells that contribute to a self-sustaining inflammatory environment. MCP-1 plays a central role in this process by promoting leukocyte recruitment into expanding adipose depots, thereby increasing the presence of macrophages and amplifying local cytokine production. Resistin, meanwhile, reflects the broader shift in adipose biology toward inflammatory and metabolically adverse signalling.[15]

The broader importance of resistin and MCP-1 lies in the fact that they blur the distinction between endocrine signaling and immune-cell trafficking. In obesity, adipose tissue acts not only as a hormonal organ but also as an inflammatory signaling center that recruits immune cells, modulates tissue composition, and reshapes local endocrine output. This makes adipose tissue a central site of immune-metabolic crosstalk. Through such mediators, obesity promotes a cycle in which inflammation worsens metabolic dysfunction, and metabolic stress further intensifies inflammation.

Resistin and MCP-1 therefore help illustrate why metabolic syndrome cannot be explained by caloric excess alone. The disorder is also driven by altered communication between adipose tissue and the immune system. These mediators contribute to the transformation of adipose tissue into a chronic inflammatory niche, one capable of influencing insulin sensitivity, tissue remodeling, and systemic metabolic risk.[16]

Schematic representation illustrating how adipose tissue expansion promotes macrophage infiltration and inflammatory signaling through mediators such as MCP-1 and resistin. These interactions contribute to immune–metabolic dysfunction, leading to insulin resistance, chronic inflammation, and adverse metabolic outcomes.

PAI-1 and the Adipose Renin-Angiotensin System

The endocrine role of adipose tissue extends beyond glucose and lipid metabolism to include the regulation of thrombosis, vascular biology, and blood pressure homeostasis. PAI-1 is a particularly important example because adipose production of this mediator links obesity to impaired fibrinolysis and the prothrombotic state frequently observed in metabolic syndrome. Its relevance lies not only in coagulation biology but also in demonstrating that adipose tissue can influence cardiovascular risk through endocrine pathways. In this sense, adipose tissue participates directly in hemostatic balance and vascular disease susceptibility, thereby broadening the concept of adipose dysfunction beyond insulin resistance alone. PAI-1 is especially significant because it helps connect excess adiposity with one of the less frequently emphasized but clinically important aspects of metabolic syndrome: altered thrombotic tendency. When adipose tissue becomes dysfunctional, its secretory profile begins to favor mediators that promote vascular and inflammatory risk. PAI-1 is emblematic of this shift. Its presence reinforces the idea that adipose tissue is capable of influencing systemic physiology in ways that extend well beyond energy storage and nutrient metabolism.[17]

Similarly, the expression of angiotensinogen and related components within adipose tissue supports the existence of a local adipose renin-angiotensin system. This is particularly important because it places adipose tissue within the regulation of vascular tone, tissue remodeling, adipocyte biology, and blood pressure control. Rather than being influenced only by circulating endocrine systems, adipose tissue can itself contribute to vasoactive signaling. In obesity, this local endocrine network may become increasingly relevant to the development of hypertension, endothelial dysfunction, and structural changes within adipose depots. Together, PAI-1 and the adipose renin-angiotensin system demonstrate that adipose tissue

is intimately involved in cardiovascular as well as metabolic regulation. They expand the endocrine profile of adipose tissue to include mediators that affect fibrinolysis, vascular reactivity, and tissue remodeling, thereby linking obesity to the hemodynamic and thrombotic abnormalities commonly associated with metabolic syndrome.[18]



Figure 2: Resistin and MCP-1 in immune–metabolic crosstalk during obesity

RBP4 and Adipose-Mediated Inter-Organ Communication

Adipose tissue communicates with distant organs not only through classical adipokines, but also through a broad and increasingly recognized range of signaling proteins, carrier molecules, and extracellular mediators that participate in inter-organ metabolic regulation. Among these, retinol-binding protein 4 (RBP4) has attracted particular attention as a mediator linking adipose dysfunction to systemic metabolic disturbance. Its significance lies in showing that adipose-derived signals are not limited to hormones traditionally associated with appetite or insulin sensitivity, but may also include proteins involved in nutrient transport, inflammatory signaling, and broader endocrine communication. In this respect, RBP4 has helped expand the conceptual framework of adipose tissue from a source of a few well-known adipokines to a complex secretory organ with diverse systemic influences.

The importance of adipose-mediated communication becomes even clearer when adipose tissue is considered within the wider network of organ crosstalk that governs metabolic homeostasis. Adipose depots interact functionally with the liver, skeletal muscle, pancreas, vasculature, and immune tissues, and this communication occurs through multiple molecular routes. Recent work has reinforced the idea that adipose tissue can influence pancreatic islet biology through adipocyte-derived extracellular vesicle signaling, highlighting that the endocrine actions of adipose tissue extend beyond soluble proteins alone. Such observations broaden the adipokine field beyond the classic leptin-adiponectin axis and emphasize that adipose tissue can shape the function of distant organs through both conventional and nonconventional signaling pathways.[19]

This diversity of endocrine output is particularly relevant in obesity and metabolic syndrome, where adipose tissue undergoes secretory reprogramming. In metabolically healthy states, adipose-derived signals contribute to coordinated regulation of insulin sensitivity, substrate partitioning, and tissue adaptation. In obesity, however, the expanding adipose organ begins to release a profile of mediators that is more strongly associated with inflammation, altered lipid handling, endocrine stress, and dysfunctional inter-organ communication. Signals such as RBP4 illustrate how adipose tissue can influence systemic metabolism not merely through energy storage capacity, but through active modulation of metabolic pathways in distant tissues. The broader importance of RBP4 and related mediators lies in the recognition that adipose endocrine biology is

heterogeneous and cannot be reduced to a single dominant pathway. Adipose tissue does not communicate through one universal signal; rather, it functions through a network of complementary and sometimes opposing mediators that influence different target organs in different ways. This heterogeneity helps explain why obesity gives rise to a wide range of metabolic consequences, from insulin resistance to altered pancreatic function and cardiometabolic risk. Thus, adipose-mediated inter-organ communication should be understood as a central feature of metabolic disease, with RBP4 serving as one example of the expanding biochemical repertoire through which adipose tissue exerts endocrine control.[20]

Chemerin and Omentin as Contrasting Endocrine Cues

Adipose tissue secretes mediators that may either worsen or counter metabolic dysfunction, and this duality is well illustrated by contrasting adipokine pathways such as those represented by chemerin and omentin. These mediators are important because they show that adipose tissue is not uniformly pathogenic or protective; rather, its endocrine effects depend on the balance between signals that promote inflammation and metabolic disturbance and those that support insulin sensitivity and vascular stability. In this way, adipose tissue behaves as a regulatory organ whose overall physiological impact reflects the composition of its secretory profile rather than the action of any single molecule.

Chemerin is generally associated with inflammatory and metabolically adverse adipose activity, whereas omentin has been more closely linked with insulin-supportive and potentially protective metabolic states. The contrast between such mediators is conceptually valuable because it illustrates how obesity is accompanied by a shift in endocrine balance rather than simply an increase in total adipokine release. As adipose tissue becomes dysfunctional, the secretome tends to move away from signals associated with metabolic flexibility and toward those associated with inflammation, endothelial stress, and insulin resistance. This altered balance contributes to the transition from relatively adaptive adipose expansion to a state of endocrine dysfunction with systemic consequences.[21]

These opposing endocrine cues also help explain why adipose tissue quality may be as important as adipose quantity. Two individuals with similar fat mass may differ substantially in metabolic risk depending on the inflammatory status, remodeling capacity, and secretory behavior of their adipose depots. Mediators such as chemerin and omentin therefore provide insight into the biological character of adipose tissue, not simply the amount of fat present. They reflect the degree to which adipose tissue remains metabolically competent or has shifted toward a dysfunctional phenotype. For this reason, chemerin- and omentin-related pathways are useful in understanding metabolic syndrome as a disorder of endocrine imbalance. The syndrome does not arise solely because adipose tissue is enlarged, but because the expanded tissue increasingly favors detrimental over protective biochemical signals. This shift amplifies systemic cardiometabolic risk and reinforces the view that adipose dysfunction is fundamentally a disorder of altered endocrine communication.[22]

Diagram showing the balance between pro-inflammatory adipokines (chemerin) and protective adipokines (omentin) in adipose tissue. Obesity shifts this balance toward a dysfunctional endocrine state, promoting inflammation, insulin resistance, and metabolic disease.

Adaptive and Stress-Associated Adipose Signaling

Obese adipose tissue may produce both pathogenic and compensatory signals simultaneously, reflecting an organ under sustained metabolic stress.[23,24] This is an important point because adipose endocrine dysfunction is not always a simple, one-directional process in which all secreted mediators are harmful. Some factors may increase as part of disease progression and contribute to worsening inflammation, insulin resistance, or tissue remodeling, whereas others may rise as an attempt to preserve metabolic balance in the face of mounting stress. The coexistence of these opposing tendencies reveals the adaptive complexity of adipose tissue during obesity.

This complexity is one reason adipose endocrine biology cannot be adequately described using a simple “good adipokine versus bad adipokine” framework. As adipose tissue expands, it is exposed to hypoxia, inflammatory activation, extracellular matrix stress, lipid overload, and vascular remodeling. In response, the tissue may generate signals that reflect injury, compensation, maladaptation, or all three simultaneously. Some adipose-derived mediators may therefore be better understood as indicators of physiological strain or attempted counter-regulation rather than as purely pathogenic molecules.[23] This broader interpretation is especially important when examining obesity-associated changes in endocrine output because it acknowledges that diseased adipose tissue remains biologically active and responsive, even when its adaptations are insufficient to restore homeostasis.

Recent work also emphasizes that adipose vascular remodeling and tissue heterogeneity strongly influence endocrine behavior. Whether adipose expansion remains metabolically adaptable or becomes pathogenic depends in part on how well the tissue maintains perfusion, structural integrity, and coordinated signaling among adipocytes, vascular cells, fibroblasts, and immune cells. In this setting, the endocrine phenotype of adipose tissue reflects not only the presence of obesity, but also the degree

to which the tissue can adapt to that burden. Endocrine dysfunction therefore emerges from failed adaptation as much as from simple enlargement of fat mass.

A dynamic view of adaptive and stress-associated adipose signaling is especially valuable for understanding metabolic syndrome. It suggests that the progression of obesity-related disease involves continual remodeling of endocrine output, with some signals reflecting early compensation and others reflecting later decompensation. This perspective highlights adipose tissue as a responsive but vulnerable organ, one whose secretory behavior evolves with disease severity and strongly influences systemic metabolic outcomes.[24]



Figure 3: Chemerin and omentin as contrasting adipose-derived endocrine signals

Adipose Endocrine Output as a Driver of Systemic Metabolic Syndrome

The full clinical impact of adipose tissue as an endocrine organ is best appreciated when its secretory products are considered collectively rather than in isolation. Obese adipose tissue releases a complex mixture of inflammatory cytokines, chemokines, vascular mediators, hormones, lipid-associated factors, and immune-related signals derived from both adipocytes and non-adipocyte cell populations. This integrated secretory network is capable of influencing insulin action, hepatic metabolism, lipid mobilization, endothelial behavior, vascular tone, and inflammatory activity across the body. As a result, the pathological importance of adipose tissue in obesity lies not only in its enlargement, but also in its capacity to reorganize systemic physiology through endocrine signaling.

This systems-level view helps explain why metabolic syndrome presents as a cluster of interconnected abnormalities rather than as a series of unrelated disorders. Central obesity, insulin resistance, dyslipidemia, hypertension, vascular dysfunction, and chronic inflammation are linked by shared endocrine and immunometabolic pathways, many of which originate in or are amplified by dysfunctional adipose tissue.[25] Adipose-derived mediators influence glucose homeostasis, lipid turnover, inflammatory tone, and vascular reactivity in parallel, thereby contributing to the integrated phenotype of metabolic syndrome. In this sense, adipose tissue acts as a central coordinating organ in the development and maintenance of cardiometabolic disease.

Understanding adipose endocrine output in this collective manner is also important therapeutically. It suggests that successful management of obesity-related metabolic disease should not focus exclusively on reducing fat mass, but also on improving adipose tissue biology itself. Interventions that limit inflammatory remodeling, preserve vascular and extracellular matrix integrity, restore healthier adipokine balance, and promote metabolically competent adipose expansion may alter systemic risk even before marked reductions in body weight occur.[26]

Clinical Implications

Understanding adipose tissue as an endocrine organ has important clinical implications. Adipokines such as adiponectin, leptin, and inflammatory cytokines may serve as potential biomarkers of metabolic risk, disease progression, and therapeutic response. Strategies aimed at reducing adipose inflammation, restoring adipokine balance, or improving adipose tissue remodeling may provide metabolic benefits beyond weight reduction alone. Interventions such as lifestyle modification, pharmacological therapies, and emerging biologic approaches may help improve adipose endocrine function and, in turn, contribute to better metabolic and cardiovascular outcomes.

CONCLUSION

Adipose tissue is now clearly recognized as a dynamic endocrine organ that plays a central role in the pathogenesis of obesity and metabolic syndrome. Through its diverse biochemical mediators, it influences insulin sensitivity, inflammation, vascular function, thrombosis, and inter-organ metabolic communication. In obesity, adipose tissue undergoes structural and functional remodeling that shifts its secretory profile toward a dysfunctional, pro-inflammatory, and metabolically adverse state. This altered endocrine output contributes not only to local adipose tissue dysfunction but also to the systemic abnormalities that characterize metabolic syndrome. Although substantial progress has been made in identifying key adipokines and inflammatory mediators, the precise mechanisms governing their interactions and clinical effects remain incompletely understood. Further research is needed to clarify these pathways and to determine how adipose-derived signals may be used as biomarkers or therapeutic targets. Overall, the endocrine behavior of adipose tissue provides a unifying framework for understanding how excess adiposity contributes to multisystem metabolic disease and offers important directions for future clinical and translational investigation.

REFERENCES

1. Kershaw, E.E. and Flier, J.S. (2004) Adipose Tissue as an Endocrine Organ. The Journal of Clinical Endocrinology &Metabolism,89,25482556.https://doi.org/10.1210/jc.2004-0395.
2. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-26749. doi:10.1074/jbc.270.45.26746.
3. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196-4200. doi:10.1210/jcem.82.12.4450.
4. Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson LMS. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab. 1998;83(11):3925-3929. doi:10.1210/jcem.83.11.5276.
5. Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia. 1998;41(1):65-71. doi:10.1007/s001250050868.
6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808. doi:10.1172/JCI19246.
7. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56(4):901-911. doi:10.2337/db06-0911.
8. Stansbury CM, Dotson GA, Pugh H, Rehemtulla A, Rajapakse I, Muir LA. A lipid-associated macrophage lineage rewires the spatial landscape of adipose tissue in early obesity. JCI Insight. 2023;8(19):e171701. doi:10.1172/jci.insight.171701.
9. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432. doi:10.1038/372425a0.
10. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995;83(7):1263-1271. doi:10.1016/0092-8674(95)90151-5.
11. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83. doi:10.1006/bbrc.1999.0255.
12. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-769. doi:10.1038/nature01705.
13. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409-2415. doi:10.1172/JCI117936.
14. Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab. 2004;89(11):5577-5582. doi:10.1210/jc.2004-0603.
15. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-312. doi:10.1038/35053000.
16. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue: implication of macrophages resident in the adipose tissue. J Clin Endocrinol Metab. 2005;90(4):2282-2289. doi:10.1210/jc.2004-1696.
17. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997;46(5):860-867.
18. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens. 2002;20(5):965-973.
19. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356-362. doi:10.1038/nature03711.
20. Zhang Y, Qian B, Yang Y, Xiao Y, Jin Y, Zhu B, et al. Visceral adipocyte-derived extracellular vesicle miR-27a-5p elicits glucose intolerance by inhibiting pancreatic beta-

cell insulin secretion. Diabetes. 2024;73(11):1832-1848. doi:10.2337/db24-0177.
21. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148(10):4687-4694. doi:10.1210/en.2007-0175.
22. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008;57(4):801-808.
23. Wei CW, Nhieu J, Lin YL, Wei LN. Modulation of adipose inflammation by cellular retinoic acid-binding protein 1. Int J Obes (Lond). 2022;46(10):1759-1769. doi:10.1038/s41366-022-01175-3.
24. Mao H, Kim GH, Pan L, Qi L. Regulation of leptin signaling and diet-induced obesity by SEL1L-HRD1 ER-associated degradation in POMC expressing neurons. Nat Commun. 2024;15:8435. doi:10.1038/s41467-024-52743-2.
25. Palomäki VA, Lehenkari P, Meriläinen S, Karttunen TJ, Koivukangas V. Dynamics of adipose tissue macrophage populations after gastric bypass surgery. Obesity (Silver Spring). 2023;31(1):184-191. doi:10.1002/oby.23602.
26. Wang L, Li J, Tang P, Zhu D, Tai L, Wang Y, et al. GSK3β deficiency expands obese adipose vasculature to mitigate metabolic disorders. Circ Res. 2025;136(1):91-111. doi:10.1161/CIRCRESAHA.124.325187.